HIF1A and neoplasm: Antiangiogenic therapies result in vascular regression and can increase intra-tumoral hypoxia levels, leading to an abnormal upregulation of HIF1-α that can stimulate tumor and stromal cells to secrete large amounts of angiogenic factors, such as FGF and ANGPT2 [334].